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Abstract
An open-label, observational Post-Marketing Surveil-
lance (PMS) study was undertaken in Germany to exam-
ine the efficacy and tolerability of donepezil in routine
clinical practice. Alzheimer’s disease (AD) patients were
treated with donepezil (5 or 10 mg once daily) and
observed for a period of approximately 3 months. Study
assessments included the Mini-Mental State Examina-
tion (MMSE), the Nurses’ Observation Scale for Geriatric
Patients (NOSGER), and adverse events (AEs). A total of
2,092 patients (mean age 73.0 years; mean B SD MMSE
score 17.8 B 5.8) were included in the efficacy assess-
ments. MMSE and NOSGER scores showed statistically
significant improvements in the total patient population
and in the subpopulations with severe AD or AD with
concomitant Parkinsonian symptoms (ADPS cohort).
AEs were reported in a total of 12% of patients and were
mostly due to peripheral cholinergic effects. In this ob-
servational PMS study, donepezil was shown to be an
effective and well-tolerated therapy in the overall patient
population, in patients with severe AD, and in the ADPS
cohort.
Copyright © 2003 S. Karger AG, Basel
Introduction
Alzheimer’s disease (AD) is a progressive debilitating
disorder estimated to affect some 5–10% of people over
65 years old and as many as 50% of those over 85 years of
age [1]. AD is characterised by degeneration of cholinergic
innervation in the cerebral cortex, and numerous trials
have evaluated cholinesterase (ChE) inhibitors as poten-
tial therapeutic agents [2]. The first two widely used ChE
inhibitors were physostigmine and tacrine. In clinical
trials with these compounds, undesirable cholinergic side
effects were reported [3–7]. The use of tacrine was also
associated with dose-limiting hepatotoxicity [3, 8]. In
addition, administration of these two drugs requires more
than once-daily dosing [9].
Donepezil hydrochloride (Aricept®) is a potent, revers-
ible, and highly selective inhibitor of acetylcholinesterase
(AChE), and, as a piperidine-based agent, it is chemically
distinct from other ChE inhibitors [10–14]. Donepezil has
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a favourable pharmacokinetic profile, eliminating the
need for dose adjustment in special populations of pa-
tients. Comparable pharmacokinetics have been demon-
strated in the young and elderly [15], and renal or hepatic
impairment does not affect the pharmacokinetics of sin-
gle-dose oral donepezil 5 mg [16, 17]. Renal impairment
also does not affect the pharmacokinetics of multiple oral
doses of 5 mg donepezil [18]. Plasma concentrations of
donepezil and AChE inhibition are increased in mild to
moderately impaired hepatic patients, following multiple
oral dose administration of 5 mg donepezil, however
treatment was safe and well tolerated in this population
[19]. Furthermore, the long dose-independent plasma
half-life of donepezil [20] allows once-daily dosing.
The efficacy and good tolerability of donepezil in treat-
ing the symptoms of AD in patients with mild to moder-
ately severe disease have been demonstrated in Phase II
and Phase III placebo-controlled trials of up to 6 months’
duration [21–24]. More recently, two extended placebo-
controlled trials have reported additional and more sus-
tained benefits. The first of these reported benefits with
donepezil on global function, cognition and activities of
daily living (ADLs) over a period of one year [25]. In the
second study, the likelihood of patients retaining func-
tional capacity over one year was significantly increased
with donepezil 10 mg/day [26]. In addition, a long-term,
open-label extension study demonstrated that donepezil
was well tolerated and provided benefits in cognition and
global function that continued for up to 2.8 years in
patients remaining on treatment, compared to historical
cohorts of untreated AD patients [27].
These studies were designed to establish the efficacy
and tolerability of donepezil and therefore, like all such
trials, were tightly controlled in order to limit the poten-
tially confounding effects of factors other than the test
treatments. In particular, patients with a range of co-
morbid medical conditions and those who were receiving
certain concomitant medications were excluded. After
approval, regulatory authorities often require additional
information on the efficacy, tolerability, and safety of a
drug in routine medical practice. One way to meet this
requirement appropriately is to conduct Post-Marketing
Surveillance (PMS) studies (‘studies of use’) in larger
cohorts of patients. In these open-label observational
studies, patients are treated with the agent under exami-
nation at the discretion of their physician, and are only
excluded from the study if the agent is contraindicated.
This paper reports on the combined results of two PMS
studies, including clinical efficacy and safety information.
These studies followed the recommendations for perform-
ing ‘studies of use’ set forth by the German Federal Insti-
tute for Medicines and Medicinal Products (BfArM, No-
vember 1998 [28]). In addition, the paper reports on an
exploratory post-hoc analysis that was performed in 2
subpopulations of patients: with severe AD, and AD with
concomitant Parkinsonian symptoms (ADPS cohort).
Methods
Study Design
Donepezil has been used in clinical practice in Germany since
October 1997. This was a Post-Marketing Surveillance (PMS) analy-
sis of combined results from two open-label, prospective, observa-
tional cohort studies undertaken mainly by office-based neurologists,
psychiatrists, and other specialists in geriatrics across Germany
between October 1997 and May 1999. A total of 580 investigators
participated. Since the aim of both studies was to collect information
on the routine (prescription) use of donepezil for the treatment of
AD, there were no inclusion or exclusion criteria for participation in
either study, apart from the current labelling for donepezil. The
length of the observation period for patients from both studies was to
be approximately 3 months. The studies were registered with the
German regulatory authority (BfArM) and the National Association
of Social Health Insurance (SHI)-Accredited Physicians (‘Kassen-
aerztliche Bundesvereinigung’ [KBV]). Recording and storage of
data were conducted according to data protection regulations.
Donepezil Treatment
In this naturalistic PMS study, no specific dosing regimens were
stipulated. Dosing was to follow the approved German labelling of
Aricept®, that is, 5 mg once daily with the possibility of increasing to
10 mg once daily after 4 to 6 weeks, based on clinicians’ judgement of
tolerability and efficacy.
Assessments
The following information was recorded at baseline: demograph-
ic characteristics, medical history, prior and current treatments for
AD, other medications, and concomitant illnesses (according to ICD-
10 classification). To evaluate efficacy, patients were assessed at
baseline and after 3 months using the Mini-Mental State Examina-
tion (MMSE) [29] and the Nurses’ Observation Scale for Geriatric
Patients (NOSGER) [30, 31].
The MMSE is the preferred cognitive assessment tool in routine
clinical practice [32]. It is a 30-point scale used to assess patients’
cognitive function across the dimensions of orientation, registration,
attention and calculation, recall, and language, and provides an esti-
mate of the severity of cognitive impairment. Scores on the MMSE
range from 0 to 30, and lower scores indicate more severe impair-
ment. The NOSGER is a 30-item questionnaire completed by the
caregiver to assess the patient with regard to the dimensions of mem-
ory, instrumental activities of daily living (IADLs), basic ADLs,
mood, social behaviour, and disturbing behaviour, each of these
dimensions consisting of five items. For each individual item, there
are five possible answers to describe the frequency of a specific
behaviour (‘all the time’, ‘most of the time’, ‘often’, ‘sometimes’,
‘never’). These answers are scored in a range from 1 to 5, thereby
yielding a total score for each dimension of 5 to 25. Higher scores
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indicate more severe disturbance or impairment. Thus, clinical
improvement will be reflected by a decline (i.e. a negative change) in
dimension scores.
At the end of the observation period, supportive parameters were
obtained by the investigator using separate global clinical judgements
of efficacy and tolerability. For efficacy assessments, investigators
rated the symptoms of AD as, ‘markedly improved’, ‘improved’, ‘un-
changed’, ‘worse’, or ‘markedly worse’. Similarly, the tolerability of
treatment with donepezil was categorised as ‘very good’, ‘good’,
‘moderate’, or ‘unsatisfactory’.
All AEs reported during the study were recorded and categorised
according to the WHO-ART (World Health Organisation, Adverse
Reaction Terminology) preferred terms and body system classifica-
tion. All Serious AEs (SAEs) were also listed and described, and
assessments (by the investigator) of their possible relation to donepe-
zil treatment were made.
Data Analysis
A descriptive analysis was performed on both efficacy and tolera-
bility data. All data analyses were performed on the respective ‘Ob-
served Cases’ (OC) population, which included those patients for
whom the data in question (e.g. MMSE at baseline and at the end of
the observation period) were available. The respective patient num-
bers are found in the Results section. No specific action was taken for
missing values.
The efficacy of donepezil was evaluated according to mean
(B SD) and median changes in the total score on the MMSE, as well
as in the separate dimension scores on the NOSGER questionnaire.
A responder analysis for the total MMSE score was undertaken by
dividing all patients completing the observation period into quartiles
according to the degree of change in total MMSE score. This pro-
vided information on the respective MMSE changes in each quartile
of the evaluable patient population.
A subgroup analysis was also undertaken to assess responses to
donepezil treatment relative to baseline cognitive impairment, cate-
gorised according to the baseline MMSE total score: mild = 19–30
points; moderate = 11–18 points; severe = 0–10 points. Changes in
MMSE total score and separate NOSGER dimension scores were
analysed for each of these three patient subgroups. A subgroup analy-
sis of treatment response also considered individual NOSGER items
such as behavioural problems and basic ADL deficiencies, analysing
the frequency of improvement (or worsening) of patients with these
particular characteristics during treatment.
In the evaluation of tolerability, subgroup analyses were per-
formed for patients with any history of cardiovascular disease,
including bradycardia. In addition, analyses of any AEs occurring in
patients taking concomitant beta blockers or selective serotonin
reuptake inhibitors (SSRIs) during donepezil treatment were also
performed and the appropriate relative risks were evaluated.
Results
Patients
A total of 2,092 patients were included in the efficacy
evaluation of donepezil in this PMS study (1,649 from
one study and 443 from the other). In the analysis of AEs,
an additional two patients were included, resulting in a
Table 1. Baseline patient characteristics
Gender, male/female, % of patients 39.2/60.8
Mean age, years (range) 73.0 (27.0–100.0)
Mean height, cm (range) 167.3 (145.0–196.0)
Mean weight, kg (range) 69.2 (39.7–115.0)
Mean baseline MMSE total score B SD
(n = 1,920) 17.8B5.8
Mild (MMSE 19–30), n (%) 953 (49.6)
Moderate (MMSE 11–18), n (%) 733 (38.2)
Severe (MMSE ^ 10), n (%) 234 (12.2)
Mean baseline NOSGER scores B SD
(n = 1,956)
Memory 15.3B4.1
Instrumental ADL 16.5B4.9
Basic ADL 9.7B4.1
Mood 12.8B3.8
Social behaviour (n = 1,957) 16.0B4.8
Disturbing behaviour (n = 1,957) 10.0B3.6
total safety population of 2,094 patients. The characteris-
tics of the patients and mean MMSE and NOSGER scores
at baseline are shown in table 1. Out of 2,073 patients for
whom diagnostic information was available, 600 (28.9%)
had a new diagnosis of AD, while 1,473 (71.1%) had pre-
existing AD. Nearly all (195%) patients enrolled were
outpatients. In patients with a prior diagnosis, the mean
(B SD) duration of AD was 31.8 B 24.3 months (range
1–216). The majority of patients (59.0%) had co-morbid
illnesses, most of which were cardiovascular (31.2%),
endocrine/metabolic (13.1%), psychiatric (13.0%) and
neurologic (9.4%) disorders. A comparable proportion of
patients (56.5%) were on concomitant medications, espe-
cially cardiovascular and central nervous system agents
(30.5% and 29.2%, respectively). Peripheral vasodilators
were taken by 13.4% of patients. Out of the entire group
of 2,092 patients enrolled, 42.9% had received prior AD
therapy (42.0% drug therapy, 3.7% other AD treatments).
The most common medications were psychoanaleptics
(classification N06 according to the Anatomical Thera-
peutic Chemical (ATC) classification, including antide-
pressants and psychostimulants/nootropics), which were
taken by 16.0% of patients.
Treatment
The mean (B SD) observation period was 3.3 B 1.1
months of donepezil treatment. Almost half of the pa-
tients for whom complete dosage information was avail-
able (885/1,949; 45.4%) had their dose changed during
this period, and in the great majority of cases this con-
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Fig. 1. Quartile analysis of change from baseline in total Mini-Men-
tal State Examination (MMSE) score (n = 415 for all).
sisted of a single increase in donepezil dosage from 5 to
10 mg. Treatment with donepezil was stopped before the
end of the planned observation period for 231 patients
(11.0% of the total population). The most common rea-
sons for discontinuation were AEs (n = 128; 6.1% of popu-
lation, 55.4% of discontinuations) and treatment failure
(n = 37; 1.8%, 16.0%). After the study was concluded,
77.1% of patients were to continue to receive treatment
with donepezil.
Efficacy
MMSE – Cognition. There were a total of 1,660
patients with recorded MMSE scores at both study base-
line and after approximately 3 months of donepezil treat-
ment. The mean B SD total MMSE score improved by
+1.4 B 3.6 points from baseline during the observation
period (p = 0.001); the median MMSE total score im-
proved by 1 point. Both mean and median changes in
MMSE total score were comparable in patients who
remained on donepezil 5 mg once daily throughout the
study and in those whose doses were increased to 10 mg
once daily.
A total of 63% of patients showed an improved MMSE
total score (61 point) compared with baseline, 36.1% of
patients improved by 63 points and 9.9% improved by
66 points. The quartile analysis of the MMSE data dem-
onstrated that the best responding quartile exhibited a
median improvement in total MMSE score from baseline
of +5 points, while the worst responding quartile exhib-
ited a median decline in score of –2 points (fig. 1).
In the subgroup analysis of MMSE total score changes
in patients with mild, moderate or severe baseline AD
symptoms (categorised according to baseline MMSE total
score), mean improvements in MMSE total score from
baseline were found to be greater in patients with more
severe baseline disease: mean B SD changes from base-
line were +0.8 B 3.4, +1.9 B 3.6, and +2.3 B 3.7 in
patients with total scores of 19–30, 11–18, and 0–10 at
baseline, respectively. The changes in MMSE total scores
were reflected in a comparison of the proportions of
patients in each dementia severity category at the end of
the observation period, relative to their initial baseline
category (table 2).
NOSGER. A total of 1,687 patients had NOSGER
assessments both at baseline and at the end of the obser-
vation period (n = 1,688 for IADL and basic ADL dimen-
sions). Statistically significant (p ! 0.001) improvements
(decreases) in all NOSGER dimension scores were seen in
this group during donepezil treatment (fig. 2). Similarly,
improvements from baseline were seen across all six
NOSGER dimensions in each disease severity group, and
the magnitude of the improvements was generally greater
in patients with moderate or severe dementia than in
those with mild disease (fig. 3).
A separate analysis of caregiver-assessed changes in
seven specific AD symptoms (individual NOSGER
Table 2. Changes in MMSE category
compared to baseline Number (%) patients in each MMSE category at the
end of the observation period
mild moderate severe
Baseline MMSE category
Mild (n = 830) 746 (89.9) 73 (8.8) 11 (1.3)
Moderate (n = 640) 226 (35.3) 368 (57.5) 46 (7.2)
Severe (n = 190) 7 (3.7) 77 (40.5) 106 (55.8)
Mild: MMSE = 19–30; moderate: MMSE = 11–18; severe: MMSE = 0–10.
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Fig. 2. Improvement in Nurses’ Observa-
tion Scale for Geriatric Patients (NOSGER)
dimension scores from baseline to the end of
the observation period (n = 1,687; * n =
1,688).
Fig. 3. Improvement in Nurses’ Observa-
tion Scale for Geriatric Patients (NOSGER)
scores from baseline to the end of the obser-
vation period in subgroups of patients with
mild (n = 790), moderate (n = 608) and se-
vere (n = 190; * n = 191) baseline AD symp-
toms (as measured by total Mini-Mental
State Examination [MMSE] score).
Table 3. Number of patients with pre-
existing behavioural problems and/or basic
ADL deficiencies with improvements,
worsening or no change in those symptoms
(according to the NOSGER)
Individual NOSGER item
(baseline/after treatment)*
Number (%) of patients
improved worsened no change
Night-time restlessness (n = 1,267/1,661) 545 (43.0) 108 (8.5) 614 (48.5)
Stubbornness (n = 1,268/1,675) 429 (33.8) 131 (10.3) 708 (55.8)
Irritability (n = 1,136/1,674) 401 (35.3) 105 (9.2) 630 (55.5)
Aggressive behaviour (n = 844/1676) 337 (39.9) 69 (8.2) 438 (51.9)
Urinary incontinence (n = 720/1,669) 233 (32.4) 74 (10.3) 413 (57.4)
Wandering (n = 583/1,667) 266 (45.6) 48 (8.2) 269 (46.1)
Bowel control problems (n = 565/1677) 204 (36.1) 56 (9.9) 305 (54.0)
* Based on ‘observed cases’ population, i.e. first number = patients with observed defi-
ciency at baseline; second number = all patients with two evaluations (baseline and after
therapy) of each NOSGER item.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:4
8:
56
 P
M
194 Dement Geriatr Cogn Disord 2003;15:189–198 Hager/Calabrese/Frölich/Göbel/Berger
Table 4. Change in investigator-rated AD symptoms in the total
study population, the severe cohort*, and the ADPS cohort
Change in
investigator-rated
AD symptoms
Total study
population
(n = 1,989)
Severe
population
(n = 222)
ADPS
population
(n = 70)
Markedly improved 226 (11.4%) 29 (13.1%) 12 (17.1%)
Improved 887 (44.6%) 96 (43.2%) 35 (50.0%)
Unchanged 640 (32.2%) 66 (29.7%) 14 (20.0%)
Worsened 139 (7.0%) 20 (9.0%) 6 (8.6%)
Markedly worsened 51 (2.6%) 6 (2.7%) 3 (4.3%)
Not evaluable 46 (2.3%) 5 (2.3%) –
* MMSE = 0–10.
ADPS = Alzheimer’s disease and Parkinsonian symptoms.
Table 5. Investigator-rated tolerability of donepezil treatment for
the total study population, the severe cohort*, and the ADPS cohort
Investigator-rated
tolerability of
donepezil treatment
Total study
population
(n = 1,989)
Severe
population
(n = 223)
ADPS
population
(n = 72)
Very good 1,061 (53.3%) 126 (56.5%) 41 (56.9%)
Good 754 (37.9%) 75 (33.6%) 25 (34.7%)
Moderate 76 (3.8%) 11 (4.9%) 1 (1.4%)
Unsatisfactory 98 (4.9%) 11 (4.9%) 5 (6.9%)
* MMSE = 0–10.
ADPS = Alzheimer’s disease and Parkinsonian symptoms.
Table 6. Number (%) of patients reporting
AEs during the observation period (only
events with an incidence of 60.5% are
listed)
AE Patients (%)
(n = 2,094)
Any AE 256 (12.2)
Nausea 46 (2.2)
Diarrhoea 30 (1.4)
Trembling inside 30 (1.4)
Vomiting 24 (1.1)
Dizziness 15 (0.7)
Restlessness 13 (0.6)
Tiredness 12 (0.6)
Confusion 10 (0.5)
items) was also performed, for those patients having
behavioural problems and/or basic ADL deficiencies at
baseline. There were consistently more patients showing
improvements in these NOSGER items than patients
showing deterioration (table 3).
Global Assessments of Change. Data from investiga-
tors’ global assessments of changes in AD symptoms from
baseline to the end of the observation period were avail-
able for 1,989 patients. More than half of these patients
showed some degree of improvement (table 4). Global
assessments of changes in symptoms were similar in
patients with severe AD (table 4).
Tolerability
Global Assessments of Tolerability. Global tolerability
of donepezil during the observation period was judged by
the investigators to be ‘very good’ or ‘good’ in 1,815
(91.3%) of a total of 1,989 assessed patients (table 5). In
the subgroup with severe AD, the global tolerability was
‘very good’ or ‘good’ in 90.1% of patients (table 5).
Adverse Events (AEs). At least one AE was reported in
256/2,094 (12.2%) patients in the total patient population
and in 29/234 (12.4%) patients with severe AD. Overall,
the most commonly reported AEs were psychiatric
(4.4%), gastrointestinal (4.1%) and neurological (2.7%).
Individual AEs with incidence greater than 0.5% are
listed in table 6. The proportion of patients remaining on
once-daily donepezil 5 mg throughout the observation
period who experienced AEs (103/1,064; 9.7%) was simi-
lar to that of patients who had one dose increase to 10 mg
once daily (52/740; 7.0%). The AE rate amongst patients
who received other dose regimes (e.g. more than one dose
alteration; n = 290) during the observation period was
higher (101/290; 34.8%), although the most common
events were still gastrointestinal, neurological or psychiat-
ric in nature. Dose reductions in patients experiencing
AEs may explain these findings.
A further subgroup analysis of the relative risks of car-
diovascular AEs, including bradycardia, did not reveal
any increase in rate of these AEs associated with donepe-
zil treatment, in patients either with or without a history
of cardiovascular conditions or previous treatment with
beta blockers. The proportion of patients experiencing
cardiovascular AEs was similar in the subgroup of pa-
tients with a history of cardiovascular conditions (11/656;
1.7%) compared with patients who had no history of car-
diovascular conditions (18/1,438; 1.3%). Low and almost
equal proportions of patients experienced bradycardia:
5/656 (0.8%) patients who had a history of cardiovascular
conditions, and 13/1,438 (0.9%) patients without a histo-
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Fig. 4. Improvement in Nurses’ Observa-
tion Scale for Geriatric Patients (NOSGER)
scores from baseline to the end of the obser-
vation period in study cohort with AD
and concomitant Parkinsonian symptoms
(ADPS cohort; n = 61) and in total study
population (n = 1,687; * n = 1,688).
ry of cardiovascular conditions. Similar relative risk anal-
yses (for any AEs) in patients who had or had not taken
concomitant beta blockers with donepezil showed compa-
rable proportions of AEs. However, patients taking con-
comitant SSRIs showed a moderate increase in the risk of
experiencing any AE during donepezil treatment. A total
of 244 patients (12.0%) who did not take concomitant
SSRIs (n = 2,036) experienced an AE, while 12 (20.7%) of
those taking SSRIs (n = 58) did experience AEs.
Serious Adverse Events (SAEs). SAEs were reported in
46/2,094 patients (2.2%), including 6/234 patients with
severe AD (2.6%). Twenty-six (56.5%) of these SAEs were
considered not related to donepezil treatment. A possible
or probable relation to donepezil treatment was judged to
be present in 10 patients, and relation to treatment was
not evaluated/evaluable for 10 patients. Four patients
experienced SAEs that were considered likely or definitely
related to donepezil (one each of transient nausea, vomit-
ing, pronounced behavioural disturbance and acute uri-
nary retention/sinus bradycardia). Fifteen deaths (0.7% of
2,094 patients) occurred, mostly from cardiovascular dis-
ease and pneumonia, but none of these were considered to
be related to donepezil treatment.
Subpopulation with AD and Concomitant
Parkinsonian Symptoms (ADPS Cohort)
In a post-hoc analysis, a subgroup of 73 patients was
identified with documented co-morbidity of Parkinso-
nian symptoms (Morbus Parkinson/Parkinson syndrome/
parkinsonism). The validity of this cohort was confirmed
by a high prevalence of anti-parkinsonian co-medication
in these patients. The baseline dementia severity (mean
MMSE at study entry: 17.8 B 5.6) in the subgroup was
identical to that in the overall study population. The
mean improvement in the MMSE score in the ADPS
cohort was +1.7 B 3.4 (overall study population: +1.4 B
3.6). Figure 4 shows an analysis of NOSGER scores for
the ADPS cohort, indicating larger caregiver-reported
benefits across all six dimensions in the ADPS cohort
compared to the overall study population. In the global
clinical judgement of change in AD symptoms, donepezil
treatment was considered at least as effective in the ADPS
population as in the overall population (table 4).
AEs were reported in 8/73 patients in the ADPS sub-
population (11.0%), an incidence consistent with the rate
of occurrence of AEs in the overall population (12.2%).
Among the eight AEs in ADPS patients, no pattern of
motor symptom worsening could be detected. Two SAEs
were reported for the ADPS population (one death result-
ing from cardiac failure, one hospitalisation due to in-
creasing disorientation), neither of which was considered
related to donepezil. In the global clinical judgement of
tolerability rated by the investigators, donepezil treat-
ment showed the same excellent tolerability profile as in
the overall population (table 5).
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Discussion
The patients observed in this PMS study were typical
of those seen in routine medical practice who are diag-
nosed with AD. Approximately 60% were women, which
is consistent with the known sex distribution of patients
with AD [33]. Furthermore, the mean age of the patients
(73 years) was similar to the controlled clinical trials with
donepezil and comparable to the average lifespan in
Western populations [34], confirming that the population
was advanced in age. Moreover, the co-morbid conditions
reported were also typical of this population of elderly
patients with AD.
Over 60% of the patients in the present study showed
improvement on the MMSE. The mean improvement in
total MMSE score of 1.4 points during the observation
period was comparable to the improvement observed dur-
ing 3–6 months of donepezil treatment in randomised,
placebo-controlled clinical trials [21–23]. Thus, the re-
sults of this ‘real world’ post-marketing surveillance study
of the cognitive benefits of donepezil are remarkably con-
sistent with results demonstrated in previous controlled
clinical trials.
This PMS study also demonstrates that the cognitive
effects of donepezil can be substantial in patients who are
particularly responsive to the agent; a median 5-point
improvement in total MMSE score was observed for the
top 25% of responders. It is also interesting to note that a
subanalysis of cognitive response by baseline disease
severity indicated that the more severe the disease, the
greater the cognitive improvement. This suggests that the
benefits of donepezil in clinical practice may not be lim-
ited to patients with mild to moderate disease, as were
investigated in the initial clinical development pro-
gramme [21–24]. Indeed, 44% of patients who initially
had severe dementia in this study improved enough to be
classified as having mild or moderate dementia by the end
of the investigation.
In addition to the cognitive benefits demonstrated in
the PMS study, the results of the NOSGER assessment
are consistent with results of two different 1-year, ran-
domised, placebo-controlled clinical trials demonstrating
the beneficial effects of donepezil on daily functioning
and behaviour [25, 26]. In addition, as with the MMSE
results, this study provides evidence that the beneficial
effect of donepezil on functional ability was more marked
in patients with moderate or severe baseline disease. The
observation that the effect of donepezil on the basic ADL
dimension of the NOSGER was greatest in those patients
with moderate or severe disease at baseline was not unex-
pected. Deterioration in basic ADLs normally occurs only
after AD has progressed to a more advanced stage [35].
Surprisingly, however, the largest numerical improve-
ment (in the total study population) was seen in the
‘mood’ domain of the NOSGER. This corroborates anec-
dotal experience of antidepressive effects of donepezil.
A number of individual NOSGER items reflected im-
provement in specific behavioural domains. Benefits of
treatment with donepezil on behaviour have been re-
ported previously [36–39], and increased attention is
being given to this aspect of ChE inhibitor therapy.
Behavioural symptoms are typically more prevalent as the
disease progresses to the moderate and severe stages, and
this is reflected in the greater improvements seen in this
study in patients with moderate or severe disease at base-
line.
Despite the majority of patients having co-morbid ill-
nesses and taking concomitant medications, the overall
incidence of AEs reported during the observation period
was notably low at 12% of patients. Amongst the AEs
reported, nausea, vomiting and diarrhoea are typical cho-
linergic effects of cholinesterase inhibitors, as observed in
previous placebo-controlled studies [21–24]. Interesting-
ly, the incidences of the AEs recorded in this PMS study
were considerably lower (all approximately 1–2% of pa-
tients) than in the controlled trials (7% for nausea, 4% for
vomiting and 9% for diarrhoea at the 5-mg dose, and
higher rates for the 10-mg dose [40]). This may be
explained by the naturalistic character of a PMS study,
where the treating physician is likely not to ask for adverse
events as specifically as in a controlled clinical trial. It was
also evident that most patients whose donepezil dose was
increased to 10 mg were able to tolerate the treatment as
well as those who continued on the 5-mg dose. The inci-
dence of AEs and SAEs was similar among patients with
severe AD compared with the overall population, and the
profile of AEs (i.e. symptoms, body systems) was similar
in the total population and in patients with severe AD.
However, there was a relatively higher incidence of
AEs recorded amongst patients who had more than one
dose adjustment during the study. This is consistent with
findings showing a relative lack of tolerance to cholinergic
adverse effects amongst some patients after increases in
donepezil dosage that necessitates a subsequent dose
reduction. Regardless of the influence of donepezil dose
changes on the incidence of AEs (or vice versa), this PMS
study demonstrates that donepezil was particularly well
tolerated, as shown by the investigators rating tolerability
as ‘good’ or ‘very good’ in 91% of patients.
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 M
ed
izi
n 
Ba
se
l  
   
   
   
   
   
  
13
1.
15
2.
21
1.
61
 - 
10
/2
3/
20
17
 4
:4
8:
56
 P
M
Observational Study of Donepezil in
Alzheimer’s Disease
Dement Geriatr Cogn Disord 2003;15:189–198 197
In this large observational ‘study of use’, donepezil
treatment in those patients with AD and co-morbid Par-
kinsonian symptoms was at least as effective and equally
well tolerated as in the overall AD study population. This
ADPS cohort was of special interest because it was consid-
ered to be at high risk for the development of worsening
motor symptoms after treatment with a cholinergic drug
such as donepezil.
In conclusion, the combined results from two observa-
tional studies of the use of donepezil to treat AD patients
in a ‘real world’ environment confirm the cognitive and
functional benefits of the agent demonstrated in random-
ised controlled trials. They also indicate that donepezil is
well tolerated in clinical practice. In addition to the estab-
lished benefits of donepezil in patients with mild to mod-
erately severe AD, there is evidence from this study that
donepezil is effective in patients with Parkinsonian symp-
toms and with more severe disease. Results in patients
with more severe AD confirm those reported for a recent
placebo-controlled clinical trial demonstrating the effica-
cy of donepezil in AD patients with moderate to severe
disease [37]. These efficacy and tolerability results, taken
together with its once-daily dosing regimen and pharma-
cokinetic profile, which is not affected by dose, age, or
hepatic or renal impairment, demonstrate that donepezil
is an effective therapy in a broad range of patients with
AD in routine clinical practice.
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